NASDAQ:VXRT Vaxart (VXRT) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free VXRT Stock Alerts $0.73 -0.02 (-2.68%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$0.69▼$0.7550-Day Range$0.66▼$1.3052-Week Range$0.53▼$1.59Volume2.14 million shsAverage Volume1.92 million shsMarket Capitalization$128.90 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vaxart alerts: Email Address Vaxart MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside334.1% Upside$3.00 Price TargetShort InterestBearish10.37% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.97 out of 5 starsMedical Sector767th out of 909 stocksBiotechnology Industry7th out of 15 stocks 3.5 Analyst's Opinion Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxart has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.37% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Vaxart has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VXRT. Previous Next 1.8 News and Social Media Coverage News SentimentVaxart has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vaxart this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat Follows10 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 18.05% of the stock of Vaxart is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.45) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Vaxart Stock (NASDAQ:VXRT)Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.Read More VXRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VXRT Stock News HeadlinesApril 30, 2024 | globenewswire.comVaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating MothersApril 26, 2024 | americanbankingnews.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average of $0.88May 3, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...April 9, 2024 | investorplace.comElection Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?March 27, 2024 | globenewswire.comVaxart to Present at World Vaccine Congress Washington 2024 on April 3March 20, 2024 | globenewswire.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 17, 2024 | finance.yahoo.comEstimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)March 15, 2024 | finance.yahoo.comVaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call TranscriptMay 3, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...March 14, 2024 | investorplace.comVXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023March 14, 2024 | finance.yahoo.comVaxart Inc (VXRT) Reports Full Year 2023 Financial ResultsMarch 14, 2024 | globenewswire.comVaxart Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 7, 2024 | globenewswire.comVaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14March 6, 2024 | marketwatch.comVaxart Names Steven Lo President, Chief ExecutiveMarch 6, 2024 | globenewswire.comVaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and DirectorFebruary 20, 2024 | finance.yahoo.comVAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?February 5, 2024 | finance.yahoo.comVaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 ChallengeJanuary 16, 2024 | marketwatch.comVaxart CEO Resigns; Biotech Raises $10 Million in Stock SaleJanuary 16, 2024 | finance.yahoo.comVaxart, Inc. Announces Management ChangeJanuary 16, 2024 | finance.yahoo.comVaxart Announces $10.0 Million Registered Direct Offering with RA Capital ManagementDecember 21, 2023 | finance.yahoo.comVaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersNovember 7, 2023 | finance.yahoo.comHere's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash WiselyNovember 3, 2023 | finance.yahoo.comVaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | finance.yahoo.comVaxart Inc (VXRT) Reports Q3 2023 Financial Results and Business UpdatesNovember 2, 2023 | finance.yahoo.comVaxart Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comVaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersOctober 26, 2023 | finance.yahoo.comVaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2See More Headlines Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees109Year Founded2004Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+300.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,460,000.00 Net Margins-1,117.56% Pretax Margin-1,114.03% Return on Equity-108.45% Return on Assets-73.31% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual Sales$7.38 million Price / Sales17.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.97Miscellaneous Outstanding Shares176,840,000Free Float171,533,000Market Cap$132.45 million OptionableOptionable Beta0.72 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Steven Lo (Age 57)President, CEO & Director Mr. Phillip Eric Lee (Age 36)CFO, Principal Financial Officer & Principal Accounting Officer Dr. Raymond D. Stapleton Jr. (Age 53)Ph.D., Chief Technology Officer Ms. Shaily Jaini GargSenior Vice President of Clinical Development & Project ManagementDr. Rajesh Kapoor Ph.D.Senior Vice President of QualityKey CompetitorsDBV TechnologiesNASDAQ:DBVTOmega TherapeuticsNASDAQ:OMGAOutlook TherapeuticsNASDAQ:OTLKCardiol TherapeuticsNASDAQ:CRDLMolecular PartnersNASDAQ:MOLNView All CompetitorsInstitutional OwnershipPFG Investments LLCBought 29,450 shares on 4/22/2024Ownership: 0.017%Kingswood Wealth Advisors LLCBought 25,000 shares on 4/15/2024Ownership: 0.014%Private Portfolio Partners LLCSold 8,500 shares on 2/7/2024Ownership: 0.067%View All Institutional Transactions VXRT Stock Analysis - Frequently Asked Questions Should I buy or sell Vaxart stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VXRT shares. View VXRT analyst ratings or view top-rated stocks. What is Vaxart's stock price target for 2024? 2 Wall Street research analysts have issued 1-year price targets for Vaxart's shares. Their VXRT share price targets range from $2.00 to $4.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 334.1% from the stock's current price. View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts. How have VXRT shares performed in 2024? Vaxart's stock was trading at $0.5728 on January 1st, 2024. Since then, VXRT shares have increased by 20.7% and is now trading at $0.6911. View the best growth stocks for 2024 here. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) released its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03. The biotechnology company earned $3.25 million during the quarter, compared to analyst estimates of $0.45 million. Vaxart had a negative trailing twelve-month return on equity of 108.45% and a negative net margin of 1,117.56%. What ETF holds Vaxart's stock? Amplify Treatments, Testing and Advancements ETF holds 39,829 shares of VXRT stock, representing 0.33% of its portfolio. When did Vaxart's stock split? Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), Organigram (OGI) and Novan (NOVN). Who are Vaxart's major shareholders? Vaxart's stock is owned by a number of retail and institutional investors. Top institutional investors include PFG Investments LLC (0.02%) and Kingswood Wealth Advisors LLC (0.01%). Insiders that own company stock include Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker, W Mark Watson and Wouter Latour. View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VXRT) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupCould Your Accounts Be Frozen?Allegiance GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Gold Grab of the CenturyColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
